Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVX-001
- Development stage
- Preclinical
- Lead developer
- ReNewVax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RVX-001 is a preclinical-stage recombinant protein vaccine candidate developed by ReNewVax for the prevention of diseases caused by *Streptococcus pneumoniae* (pneumococcus). Unlike traditional pneumococcal conjugate vaccines (PCVs) that target a limited number of capsular polysaccharide serotypes, RVX-001 utilizes conserved protein antigens found across all known serotypes of the bacterium. This approach is intended to provide universal protection and circumvent the issue of serotype replacement, where non-vaccine serotypes emerge to cause disease. The program is currently being evaluated for the prevention of pneumonia, septicaemia, and meningitis.
02
Targets
Pneumococcal protein antigensStreptococcus pneumoniae conserved antigens
Beyond the preview
Go deeper on RVX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RVX-001.